MolecuLight Receives Innovative Technology Contract from Vizient for its i:X® Fluorescence Wound Imaging Device

May 4, 2021 -Contract Awarded for Products that Bring Improvement to the Health Care Industry

PITTSBURGH, PA – (May 4, 2021) MolecuLight Corp., the leader in point-of-care fluorescence imaging for detection of wounds containing elevated bacterial loads, announces its MolecuLight i:X® fluorescence wound imaging device has received an Innovative Technology contract from

… Read More

MolecuLight Announces the Appointment of 11 Global Distributors

April 8, 2021 -Distributors’ Extensive Support and Technical Expertise will Meet Growing Global Demand for the MolecuLight i:X® Fluorescence Wound Imaging Device

Toronto, Canada – (April 8, 2021) MolecuLight Inc., the leader in point-of-care fluorescence imaging for detection of wounds containing elevated bacterial loads, announced that it has appointed 11 specialized… Read More

Results Published in Study Show MolecuLight Fluorescence Point-of-Care Imaging Detected Pseudomonas Aeruginosa (PA) in Wounds with a PPV of 93%

March 2, 2021 -Study Reveals the Utility of Cyan Fluorescence to Reliably Predict Pseudomonas, a Bacterial Pathogen that Precludes Wound Healing and Often Evades Conventional Treatment Methods

Toronto, Canada – (March 2, 2021) MolecuLight Inc., the leader in point-of-care fluorescence imaging for point-of-care detection of wounds containing elevated bacterial

… Read More

Wound Care Plus, LLC Adopts the MolecuLight i:X® as a Standard Point-of-Care Device for its Wound Care Service Offering to the Long-Term Care and Extended Care Markets

December 10, 2020 -MolecuLight i:X will Provide Essential Real-Time Information to Assist Wound Care Plus’s Advanced Wound Care Consultants in Providing the Highest Quality Wound Care

Toronto, Canada and Midwest, USA – (December 10, 2020) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing bacteria, announced that Wound

… Read More

Results Published from 2-Year Study of 229 Wounds Treated in an NHS Clinic Show Fluorescence Point-of-Care Imaging Improved Wound Healing Rates by 23%

November 25, 2020 -Results of Fluorescence Imaging Combined with Clinical Assessment

Toronto, Canada and London, UK – (November 25, 2020) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing bacteria, announced the publication of results from a 2-year retrospective study of 229 foot ulcers in… Read More

Results from 350-Patient FLAAG Trial Show MolecuLight Point-of-Care Imaging Improves Detection of High Bacterial Burden in Wounds Four-fold over Standard of Care Assessment

September 29, 2020 -Fluorescence Imaging Use Led to Changes to 69% of Treatment Plans

Toronto, CANADA – (September 29, 2020) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of bacteria in wounds, announced publication of results from the Fluorescence Imaging Assessment and Guidance (“FLAAG”) clinical trial in… Read More